HP802-247 - Revision history

WikiModEn2: Wikify.

2022-11-01T15:30:36Z

Wikify.

← Older revision		Revision as of 15:30, 1 November 2022
Line 1:		Line 1:
	~~HP802-247~~ is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose [[skin]] will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be [[skin]] graft.<ref>{{REFweb		'''{{FULLPAGENAME}}''' is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose [[skin]] will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be [[skin]] graft.<ref>{{REFweb
	\|last=		\|last=
	\|first=		\|first=
Line 12:		Line 12:
	The new spray (HP802-247) consisted of a combination of donated [[skin]] cells and proteins.		The new spray (HP802-247) consisted of a combination of donated [[skin]] cells and proteins.

	The study was conducted by researchers from the {{UNI\|University of Miami\|UMiami}} and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb		The study was conducted by researchers from the {{UNI\|University of Miami\|UMiami}} and other institutions in the [[United States]] and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal ''The Lancet''.<ref>{{REFweb
	\|last=		\|last=
	\|first=		\|first=
Line 22:		Line 22:
	}}</ref>		}}</ref>

	The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the [[skin]], and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.		The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the [[skin]], and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn [[foreskin]] samples (removed during [[circumcision]]). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.

	{{REF}}		{{REF}}

WikiAdmin: wikify skin

2021-12-27T14:22:40Z

wikify skin

← Older revision		Revision as of 14:22, 27 December 2021
Line 1:		Line 1:
	HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>{{REFweb		HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose [[skin]] will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be [[skin]] graft.<ref>{{REFweb
	\|last=		\|last=
	\|first=		\|first=
Line 10:		Line 10:

	== HP802-247 ==		== HP802-247 ==
	The new spray (HP802-247) consisted of a combination of donated skin cells and proteins.		The new spray (HP802-247) consisted of a combination of donated [[skin]] cells and proteins.

	The study was conducted by researchers from the {{UNI\|University of Miami\|UMiami}} and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb		The study was conducted by researchers from the {{UNI\|University of Miami\|UMiami}} and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb
Line 22:		Line 22:
	}}</ref>		}}</ref>

	The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.		The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the [[skin]], and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.

	{{REF}}		{{REF}}

WikiAdmin: using UNI template

2021-12-11T22:39:51Z

using UNI template

← Older revision		Revision as of 22:39, 11 December 2021
Line 12:		Line 12:
	The new spray (HP802-247) consisted of a combination of donated skin cells and proteins.		The new spray (HP802-247) consisted of a combination of donated skin cells and proteins.

	The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb		The study was conducted by researchers from the {{UNI\|University of Miami\|UMiami}} and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb
	\|last=		\|last=
	\|first=		\|first=

WikiAdmin: using singular name for category

2021-11-29T13:13:57Z

using singular name for category

← Older revision		Revision as of 13:13, 29 November 2021
Line 26:		Line 26:
	{{REF}}		{{REF}}

	[[Category:Foreskin ~~products~~]]		[[Category:Foreskin product]]
	[[Category:Financial gain]]		[[Category:Financial gain]]

WikiAdmin: add interlanguage link

2019-11-22T20:40:53Z

add interlanguage link

← Older revision		Revision as of 20:40, 22 November 2019
Line 31:		Line 31:
	[[Category:From CircLeaks]]		[[Category:From CircLeaks]]
	[[Category:From IntactWiki]]		[[Category:From IntactWiki]]

			[[de:{{FULLPAGENAME}}]]

WikiAdmin: decapitalize category names

2019-10-19T18:30:15Z

decapitalize category names

← Older revision		Revision as of 18:30, 19 October 2019
Line 1:		Line 1:
	HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>{{REFweb		HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>{{REFweb
	\| last=		\|last=
	\| first=		\|first=
	\| date=2012-08-03		\|date=2012-08-03
	\| title=Spray-on-skin' treatment for leg ulcers		\|title=Spray-on-skin' treatment for leg ulcers
	\| url=http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx		\|url=http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx
	\| publisher=NHS		\|publisher=NHS
	\| accessdate=2012-11-24		\|accessdate=2012-11-24
	}}</ref>		}}</ref>

Line 13:		Line 13:

	The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb		The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb
	\| last=		\|last=
	\| first=		\|first=
	\| date=201209		\|date=201209
	\| title=Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial		\|title=Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
	\| url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract		\|url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract
	\| publisher=The Lancet		\|publisher=The Lancet
	\| accessdate=2012-11-24		\|accessdate=2012-11-24
	}}</ref>		}}</ref>

Line 26:		Line 26:
	{{REF}}		{{REF}}

	[[Category:Foreskin ~~Products~~]]		[[Category:Foreskin products]]
	[[Category:Financial ~~Gain~~]]		[[Category:Financial gain]]

	[[Category:From CircLeaks]]		[[Category:From CircLeaks]]
	[[Category:From IntactWiki]]		[[Category:From IntactWiki]]

WikiAdmin at 14:55, 14 September 2019

2019-09-14T14:55:18Z

← Older revision		Revision as of 14:55, 14 September 2019
Line 28:		Line 28:
	[[Category:Foreskin Products]]		[[Category:Foreskin Products]]
	[[Category:Financial Gain]]		[[Category:Financial Gain]]
	~~[[Category:CircLeaks]]~~

			[[Category:From CircLeaks]]
	[[Category:From IntactWiki]]		[[Category:From IntactWiki]]

WikiAdmin at 18:49, 18 August 2019

2019-08-18T18:49:24Z

← Older revision		Revision as of 18:49, 18 August 2019
Line 1:		Line 1:
	~~{{Construction Site}}~~		HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>{{REFweb
			\| last=
	HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>		\| first=
	{{~~cite web~~		\| date=2012-08-03
	\| url = http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx		\| title=Spray-on-skin' treatment for leg ulcers
	\| ~~title~~ = ~~'Spray-on-skin' treatment for leg ulcers~~		\| url=http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx
	\| accessdate = 2012-11-24		\| publisher=NHS
	~~\| date = 2012-08-03~~		\| accessdate=2012-11-24
	~~\| publisher = NHS~~		}}</ref>
	}}
	</ref>

	== HP802-247 ==		== HP802-247 ==

	The new spray (HP802-247) consisted of a combination of donated skin cells and proteins.		The new spray (HP802-247) consisted of a combination of donated skin cells and proteins.

	The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>		The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb
	{{~~cite web~~		\| last=
	\| ~~url~~ = ~~http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract~~		\| first=
	\| title = Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial		\| date=201209
	\| ~~accessdate~~ = ~~2012~~-11-24		\| title=Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
	\| ~~date~~ = ~~201209~~		\| url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract
	\| ~~publisher~~ = ~~The Lancet~~		\| publisher=The Lancet
	}}		\| accessdate=2012-11-24
	</ref>		}}</ref>

	The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.		The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.

			{{REF}}

	~~==References==~~
	~~<div class='references-small'>~~
	~~<references/>~~
	~~</div>~~

	[[Category:Foreskin Products]]		[[Category:Foreskin Products]]
Line 38:		Line 30:
	[[Category:CircLeaks]]		[[Category:CircLeaks]]

	~~[[Category:Construction Site]]~~
	[[Category:From IntactWiki]]		[[Category:From IntactWiki]]

WikiAdmin: Created page with "{{Construction Site}} HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin wil..."

2019-08-16T14:41:12Z

Created page with "{{Construction Site}} HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin wil..."

New page

{{Construction Site}}

HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>
{{cite web
| url = http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx
| title = 'Spray-on-skin' treatment for leg ulcers
| accessdate = 2012-11-24
| date = 2012-08-03
| publisher = NHS
}}
</ref>

== HP802-247 ==

The new spray (HP802-247) consisted of a combination of donated skin cells and proteins.

The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>
{{cite web
| url = http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract
| title = Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
| accessdate = 2012-11-24
| date = 201209
| publisher = The Lancet
}}
</ref>

The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.

==References==
<div class='references-small'>
<references/>
</div>

[[Category:Foreskin Products]]
[[Category:Financial Gain]]
[[Category:CircLeaks]]

[[Category:Construction Site]]
[[Category:From IntactWiki]]